+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Nanomaterial-Based Adjuvants Vaccine Market - Global Forecast 2026-2032- Product Image
Nanomaterial-Based Adjuvants Vaccine Market - Global Forecast 2026-2032- Product Image
Sale

Nanomaterial-Based Adjuvants Vaccine Market - Global Forecast 2026-2032

  • Report

  • 198 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6120499
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Nanomaterial-Based Adjuvants Vaccine Market is projected to reach USD 2.30 Billion in 2026. It is expected to continue growing at a CAGR of 10.01%, reaching USD 4.08 Billion by 2032.

Nanomaterial-Based Adjuvants Are Reshaping Vaccine Formulation Priorities

Nanomaterial-based adjuvants use engineered materials to enhance antigen presentation, immune activation, delivery, or release control. Their relevance is tied to the need for vaccines that generate durable protection, support dose sparing, improve stability, and address difficult targets. The field remains closely linked to formulation safety, reproducible manufacturing, regulatory characterization, and evidence of clinical benefit.

Platform Convergence Is Accelerating More Precise Immune Engineering

The landscape is shifting from broadly stimulatory adjuvants toward platforms designed to control where, when, and how antigens interact with immune cells. Lipid nanoparticles, polymeric systems, inorganic particles, virus-like structures, and hybrid materials are being evaluated for distinct delivery and immunological functions. Progress increasingly depends on integrating material science with systems immunology, scalable process development, and standardized analytical methods.

Artificial Intelligence Is Compressing Discovery and Optimization Cycles

Artificial intelligence can support nanomaterial-based adjuvant development by linking particle characteristics with cellular uptake, cytokine profiles, biodistribution, and formulation stability. Machine-learning models may help prioritize compositions, identify experimental conditions, and detect relationships across complex datasets, while automation can improve repeatability in screening. However, limited standardized datasets, biological variability, interpretability requirements, and the need for experimentally validated safety evidence constrain deployment.

Regional Ecosystems Differ in Research Depth, Manufacturing, and Regulatory Readiness

North America combines advanced vaccine research, translational infrastructure, and strong capabilities in nanomedicine. Europe emphasizes collaborative research, quality-by-design development, and coordinated regulatory expectations. Asia-Pacific benefits from substantial biomanufacturing capacity and active technology development, with capabilities varying across economies. Latin America is strengthening vaccine and biotechnology capacity while addressing technology-access and scale-up constraints. The Middle East is investing in life-science infrastructure and partnerships, whereas Africa’s priorities include locally relevant vaccine production, resilient supply chains, and accessible technologies.

International Groupings Shape Standards, Funding, and Technology Access

ASEAN cooperation is relevant to regional manufacturing, procurement, and regulatory alignment. BRICS members provide diverse research, production, and public-health capabilities, but coordination and technical harmonization remain uneven. The European Union supports cross-border research and common regulatory structures. G7 economies contribute substantial scientific, financial, and manufacturing capabilities. GCC states are developing biotechnology and healthcare infrastructure, while NATO members create research and preparedness networks whose relevance extends to platform resilience and biodefense applications.

Country Capabilities Range From Discovery Leadership to Manufacturing Expansion

The United States and Canada maintain strong academic, biotechnology, and translational ecosystems. The United Kingdom, France, Germany, Italy, and Spain contribute through advanced biomedical research, public institutions, and European collaboration. China, Japan, South Korea, India, and Australia combine research activity with growing or established vaccine-manufacturing capabilities, though regulatory and commercialization pathways differ. Brazil and Mexico are important Latin American contributors to public-health production and research. Russia retains scientific and manufacturing capabilities, with international collaboration shaped by geopolitical and regulatory conditions.

Leaders Should Prioritize Safety, Standardization, and Translational Proof

Industry leaders should define target product profiles before selecting nanomaterials, linking particle attributes to a measurable immunological advantage. Development programs should use standardized assays for size, morphology, surface chemistry, aggregation, impurities, release, biodistribution, and immune response. Early engagement with regulators, validated scale-up processes, robust comparability plans, and transparent risk assessment can reduce late-stage uncertainty. Partnerships spanning materials science, vaccine development, clinical research, and manufacturing can help convert promising laboratory findings into reproducible products.

The Assessment Uses Structured Evidence Across Science, Policy, and Development

The research approach combines review of peer-reviewed studies, clinical and preclinical evidence, regulatory materials, public-health programs, patent activity, manufacturing developments, and authoritative institutional sources. Findings are synthesized by technology type, application, geography, and stakeholder group, with attention to demonstrated performance, safety considerations, manufacturability, and implementation context. Interpretations distinguish established evidence from emerging research and avoid treating laboratory potential as clinical validation.

Successful Adoption Will Depend on Demonstrated Benefit and Manufacturability

Nanomaterial-based adjuvants offer a route toward more targeted and adaptable vaccine design, but scientific promise alone will not ensure adoption. Durable progress requires evidence that improved immune responses translate into meaningful clinical and public-health benefits without unacceptable safety, cost, or production burdens. Developers that combine disciplined materials characterization, artificial-intelligence-assisted discovery, regulatory alignment, and scalable manufacturing will be better positioned to advance the field responsibly.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Nanomaterial-Based Adjuvants Vaccine Market, by Vaccine Formulation
7.1. Introduction
7.2. Conjugate
7.3. DNA
7.4. mRNA
7.4.1. Ionizable Lipid
7.4.2. Pegylated Lipid
7.5. Protein Subunit
7.6. Viral Vector
8. Nanomaterial-Based Adjuvants Vaccine Market, by Nanomaterial Type
8.1. Introduction
8.2. Inorganic Nanoparticles
8.2.1. Gold
8.2.2. Silica
8.3. Lipid Nanoparticles
8.3.1. Nanolipid Carriers
8.3.2. Solid Lipid Nanoparticles
8.4. Polymer Nanoparticles
8.4.1. Chitosan
8.4.2. PLGA
8.5. Virus-Like Particles
8.5.1. Bacteriophage VLP
8.5.2. Plant Virus VLP
9. Nanomaterial-Based Adjuvants Vaccine Market, by Application
9.1. Introduction
9.2. Allergy
9.3. Autoimmune Disorders
9.4. Infectious Diseases
9.4.1. Bacterial Infections
9.4.2. Viral Infections
9.5. Oncology
9.5.1. Hematological Malignancies
9.5.2. Solid Tumors
10. Nanomaterial-Based Adjuvants Vaccine Market, by Route Of Administration
10.1. Introduction
10.2. Intradermal
10.3. Intramuscular
10.4. Nasal
10.4.1. Drops
10.4.2. Spray
10.5. Oral
10.6. Subcutaneous
11. Nanomaterial-Based Adjuvants Vaccine Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Hospitals
11.4. Research Institutes
12. Nanomaterial-Based Adjuvants Vaccine Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Nanomaterial-Based Adjuvants Vaccine Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Nanomaterial-Based Adjuvants Vaccine Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. BioNTech SE
16.2. CSL Limited
16.3. Dynavax Technologies Corporation
16.4. GlaxoSmithKline plc
16.5. Merck & Co., Inc.
16.6. Moderna, Inc.
16.7. Novavax, Inc.
16.8. Pfizer Inc.
16.9. Sanofi S.A.
16.10. Takeda Pharmaceutical Company Limited
16.11. Vaxine Pty Ltd
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Nanomaterial-Based Adjuvants Vaccine Market, Years Considered for the Study
FIGURE 2. Global Nanomaterial-Based Adjuvants Vaccine Market, Research Design
FIGURE 3. Global Nanomaterial-Based Adjuvants Vaccine Market, Research Framework
FIGURE 4. Global Nanomaterial-Based Adjuvants Vaccine Market, Data Triangulation
FIGURE 5. Global Nanomaterial-Based Adjuvants Vaccine Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Nanomaterial-Based Adjuvants Vaccine Market Size, by Vaccine Formulation, 2025 vs 2032 (%)
FIGURE 7. Global Nanomaterial-Based Adjuvants Vaccine Market Size, by Vaccine Formulation, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Nanomaterial-Based Adjuvants Vaccine Market Size, by Nanomaterial Type, 2025 vs 2032 (%)
FIGURE 9. Global Nanomaterial-Based Adjuvants Vaccine Market Size, by Nanomaterial Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Nanomaterial-Based Adjuvants Vaccine Market Size, by Application, 2025 vs 2032 (%)
FIGURE 11. Global Nanomaterial-Based Adjuvants Vaccine Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Nanomaterial-Based Adjuvants Vaccine Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 13. Global Nanomaterial-Based Adjuvants Vaccine Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Nanomaterial-Based Adjuvants Vaccine Market Size, by End User, 2025 vs 2032 (%)
FIGURE 15. Global Nanomaterial-Based Adjuvants Vaccine Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Nanomaterial-Based Adjuvants Vaccine Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Nanomaterial-Based Adjuvants Vaccine Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Nanomaterial-Based Adjuvants Vaccine Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Nanomaterial-Based Adjuvants Vaccine Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Nanomaterial-Based Adjuvants Vaccine Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Nanomaterial-Based Adjuvants Vaccine Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Nanomaterial-Based Adjuvants Vaccine Market Segmentation & Coverage
TABLE 2. Global Nanomaterial-Based Adjuvants Vaccine Market Size, 2017-2032 (USD Million)
TABLE 3. Global Nanomaterial-Based Adjuvants Vaccine Market Size, by Vaccine Formulation, 2017-2032 (USD Million)
TABLE 4. Global Conjugate Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Conjugate Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Conjugate Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global DNA Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global DNA Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global DNA Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global mRNA Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global mRNA Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global mRNA Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Ionizable Lipid Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Ionizable Lipid Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Ionizable Lipid Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Pegylated Lipid Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Pegylated Lipid Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Pegylated Lipid Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Protein Subunit Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Protein Subunit Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Protein Subunit Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Viral Vector Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Viral Vector Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Viral Vector Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Nanomaterial-Based Adjuvants Vaccine Market Size, by Nanomaterial Type, 2017-2032 (USD Million)
TABLE 26. Global Inorganic Nanoparticles Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Inorganic Nanoparticles Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Inorganic Nanoparticles Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Gold Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Gold Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Gold Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Silica Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Silica Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Silica Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Lipid Nanoparticles Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Lipid Nanoparticles Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Lipid Nanoparticles Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Nanolipid Carriers Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Nanolipid Carriers Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Nanolipid Carriers Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Solid Lipid Nanoparticles Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Solid Lipid Nanoparticles Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Solid Lipid Nanoparticles Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Polymer Nanoparticles Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Polymer Nanoparticles Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Polymer Nanoparticles Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Chitosan Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Chitosan Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Chitosan Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global PLGA Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global PLGA Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global PLGA Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Virus-Like Particles Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Virus-Like Particles Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Virus-Like Particles Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Bacteriophage VLP Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Bacteriophage VLP Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Bacteriophage VLP Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Plant Virus VLP Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Plant Virus VLP Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Plant Virus VLP Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Nanomaterial-Based Adjuvants Vaccine Market Size, by Application, 2017-2032 (USD Million)
TABLE 63. Global Allergy Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Global Allergy Market Size, by Group, 2017-2032 (USD Million)
TABLE 65. Global Allergy Market Size, by Country, 2017-2032 (USD Million)
TABLE 66. Global Autoimmune Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Global Autoimmune Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 68. Global Autoimmune Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 69. Global Infectious Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Global Infectious Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 71. Global Infectious Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 72. Global Bacterial Infections Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Global Bacterial Infections Market Size, by Group, 2017-2032 (USD Million)
TABLE 74. Global Bacterial Infections Market Size, by Country, 2017-2032 (USD Million)
TABLE 75. Global Viral Infections Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Global Viral Infections Market Size, by Group, 2017-2032 (USD Million)
TABLE 77. Global Viral Infections Market Size, by Country, 2017-2032 (USD Million)
TABLE 78. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 80. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
TABLE 81. Global Hematological Malignancies Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Global Hematological Malignancies Market Size, by Group, 2017-2032 (USD Million)
TABLE 83. Global Hematological Malignancies Market Size, by Country, 2017-2032 (USD Million)
TABLE 84. Global Solid Tumors Market Size, by Region, 2017-2032 (USD Million)
TABLE 85. Global Solid Tumors Market Size, by Group, 2017-2032 (USD Million)
TABLE 86. Global Solid Tumors Market Size, by Country, 2017-2032 (USD Million)
TABLE 87. Global Nanomaterial-Based Adjuvants Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 88. Global Intradermal Market Size, by Region, 2017-2032 (USD Million)
TABLE 89. Global Intradermal Market Size, by Group, 2017-2032 (USD Million)
TABLE 90. Global Intradermal Market Size, by Country, 2017-2032 (USD Million)
TABLE 91. Global Intramuscular Market Size, by Region, 2017-2032 (USD Million)
TABLE 92. Global Intramuscular Market Size, by Group, 2017-2032 (USD Million)
TABLE 93. Global Intramuscular Market Size, by Country, 2017-2032 (USD Million)
TABLE 94. Global Nasal Market Size, by Region, 2017-2032 (USD Million)
TABLE 95. Global Nasal Market Size, by Group, 2017-2032 (USD Million)
TABLE 96. Global Nasal Market Size, by Country, 2017-2032 (USD Million)
TABLE 97. Global Drops Market Size, by Region, 2017-2032 (USD Million)
TABLE 98. Global Drops Market Size, by Group, 2017-2032 (USD Million)
TABLE 99. Global Drops Market Size, by Country, 2017-2032 (USD Million)
TABLE 100. Global Spray Market Size, by Region, 2017-2032 (USD Million)
TABLE 101. Global Spray Market Size, by Group, 2017-2032 (USD Million)
TABLE 102. Global Spray Market Size, by Country, 2017-2032 (USD Million)
TABLE 103. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 104. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 105. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 106. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 107. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 108. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 109. Global Nanomaterial-Based Adjuvants Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 110. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 111. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 112. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 113. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 114. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 115. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 116. Global Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 117. Global Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 118. Global Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 119. Global Nanomaterial-Based Adjuvants Vaccine Market Size, by Region, 2017-2032 (USD Million)
TABLE 120. Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Market Size, by Region, 2017-2032 (USD Million)
TABLE 121. Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Market Size, by Vaccine Formulation, 2017-2032 (USD Million)
TABLE 122. Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Market Size, by mRNA, 2017-2032 (USD Million)
TABLE 123. Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Market Size, by Nanomaterial Type, 2017-2032 (USD Million)
TABLE 124. Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Market Size, by Inorganic Nanoparticles, 2017-2032 (USD Million)
TABLE 125. Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Market Size, by Lipid Nanoparticles, 2017-2032 (USD Million)
TABLE 126. Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Market Size, by Polymer Nanoparticles, 2017-2032 (USD Million)
TABLE 127. Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Market Size, by Virus-Like Particles, 2017-2032 (USD Million)
TABLE 128. Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Market Size, by Application, 2017-2032 (USD Million)
TABLE 129. Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 130. Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 131. Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 132. Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Market Size, by Nasal, 2017-2032 (USD Million)
TABLE 133. Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 134. North America Nanomaterial-Based Adjuvants Vaccine Market Size, by Region, 2017-2032 (USD Million)
TABLE 135. North America Nanomaterial-Based Adjuvants Vaccine Market Size, by Vaccine Formulation, 2017-2032 (USD Million)
TABLE 136. North America Nanomaterial-Based Adjuvants Vaccine Market Size, by mRNA, 2017-2032 (USD Million)
TABLE 137. North America Nanomaterial-Based Adjuvants Vaccine Market Size, by Nanomaterial Type, 2017-2032 (USD Million)
TABLE 138. North America Nanomaterial-Based Adjuvants Vaccine Market Size, by Inorganic Nanoparticles, 2017-2032 (USD Million)
TABLE 139. North America Nanomaterial-Based Adjuvants Vaccine Market Size, by Lipid Nanoparticles, 2017-2032 (USD Million)
TABLE 140. North America Nanomaterial-Based Adjuvants Vaccine Market Size, by Polymer Nanoparticles, 2017-2032 (USD Million)
TABLE 141. North America Nanomaterial-Based Adjuvants Vaccine Market Size, by Virus-Like Particles, 2017-2032 (USD Million)
TABLE 142. North America Nanomaterial-Based Adjuvants Vaccine Market Size, by Application, 2017-2032 (USD Million)
TABLE 143. North America Nanomaterial-Based Adjuvants Vaccine Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 144. North America Nanomaterial-Based Adjuvants Vaccine Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 145. North America Nanomaterial-Based Adjuvants Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 146. North America Nanomaterial-Based Adjuvants Vaccine Market Size, by Nasal, 2017-2032 (USD Million)
TABLE 147. North America Nanomaterial-Based Adjuvants Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 148. Latin America Nanomaterial-Based Adjuvants Vaccine Market Size, by Region, 2017-2032 (USD Million)
TABLE 149. Latin America Nanomaterial-Based Adjuvants Vaccine Market Size, by Vaccine Formulation, 2017-2032 (USD Million)
TABLE 150. Latin America Nanomaterial-Based Adjuvants Vaccine Market Size, by mRNA, 2017-2032 (USD Million)
TABLE 151. Latin America Nanomaterial-Based Adjuvants Vaccine Market Size, by Nanomaterial Type, 2017-2032 (USD Million)
TABLE 152. Latin America Nanomaterial-Based Adjuvants Vaccine Market Size, by Inorganic Nanoparticles, 2017-2032 (USD Million)
TABLE 153. Latin America Nanomaterial-Based Adjuvants Vaccine Market Size, by Lipid Nanoparticles, 2017-2032 (USD Million)
TABLE 154. Latin America Nanomaterial-Based Adjuvants Vaccine Market Size, by Polymer Nanoparticles, 2017-2032 (USD Million)
TABLE 155. Latin America Nanomaterial-Based Adjuvants Vaccine Market Size, by Virus-Like Particles, 2017-2032 (USD Million)
TABLE 156. Latin America Nanomaterial-Based Adjuvants Vaccine Market Size, by Application, 2017-2032 (USD Million)
TABLE 157. Latin America Nanomaterial-Based Adjuvants Vaccine Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 158. Latin America Nanomaterial-Based Adjuvants Vaccine Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 159. Latin America Nanomaterial-Based Adjuvants Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 160. Latin America Nanomaterial-Based Adjuvants Vaccine Market Size, by Nasal, 2017-2032 (USD Million)
TABLE 161. Latin America Nanomaterial-Based Adjuvants Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 162. Europe Nanomaterial-Based Adjuvants Vaccine Market Size, by Region, 2017-2032 (USD Million)
TABLE 163. Europe Nanomaterial-Based Adjuvants Vaccine Market Size, by Vaccine Formulation, 2017-2032 (USD Million)
TABLE 164. Europe Nanomaterial-Based Adjuvants Vaccine Market Size, by mRNA, 2017-2032 (USD Million)
TABLE 165. Europe Nanomaterial-Based Adjuvants Vaccine Market Size, by Nanomaterial Type, 2017-2032 (USD Million)
TABLE 166. Europe Nanomaterial-Based Adjuvants Vaccine Market Size, by Inorganic Nanoparticles, 2017-2032 (USD Million)
TABLE 167. Europe Nanomaterial-Based Adjuvants Vaccine Market Size, by Lipid Nanoparticles, 2017-2032 (USD Million)
TABLE 168. Europe Nanomaterial-Based Adjuvants Vaccine Market Size, by Polymer Nanoparticles, 2017-2032 (USD Million)
TABLE 169. Europe Nanomaterial-Based Adjuvants Vaccine Market Size, by Virus-Like Particles, 2017-2032 (USD Million)
TABLE 170. Europe Nanomaterial-Based Adjuvants Vaccine Market Size, by Application, 2017-2032 (USD Million)
TABLE 171. Europe Nanomaterial-Based Adjuvants Vaccine Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 172. Europe Nanomaterial-Based Adjuvants Vaccine Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 173. Europe Nanomaterial-Based Adjuvants Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 174. Europe Nanomaterial-Based Adjuvants Vaccine Market Size, by Nasal, 2017-2032 (USD Million)
TABLE 175. Europe Nanomaterial-Based Adjuvants Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 176. Middle East Nanomaterial-Based Adjuvants Vaccine Market Size, by Region, 2017-2032 (USD Million)
TABLE 177. Middle East Nanomaterial-Based Adjuvants Vaccine Market Size, by Vaccine Formulation, 2017-2032 (USD Million)
TABLE 178. Middle East Nanomaterial-Based Adjuvants Vaccine Market Size, by mRNA, 2017-2032 (USD Million)
TABLE 179. Middle East Nanomaterial-Based Adjuvants Vaccine Market Size, by Nanomaterial Type, 2017-2032 (USD Million)
TABLE 180. Middle East Nanomaterial-Based Adjuvants Vaccine Market Size, by Inorganic Nanoparticles, 2017-2032 (USD Million)
TABLE 181. Middle East Nanomaterial-Based Adjuvants Vaccine Market Size, by Lipid Nanoparticles, 2017-2032 (USD Million)
TABLE 182. Middle East Nanomaterial-Based Adjuvants Vaccine Market Size, by Polymer Nanoparticles, 2017-2032 (USD Million)
TABLE 183. Middle East Nanomaterial-Based Adjuvants Vaccine Market Size, by Virus-Like Particles, 2017-2032 (USD Million)
TABLE 184. Middle East Nanomaterial-Based Adjuvants Vaccine Market Size, by Application, 2017-2032 (USD Million)
TABLE 185. Middle East Nanomaterial-Based Adjuvants Vaccine Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 186. Middle East Nanomaterial-Based Adjuvants Vaccine Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 187. Middle East Nanomaterial-Based Adjuvants Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 188. Middle East Nanomaterial-Based Adjuvants Vaccine Market Size, by Nasal, 2017-2032 (USD Million)
TABLE 189. Middle East Nanomaterial-Based Adjuvants Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 190. Africa Nanomaterial-Based Adjuvants Vaccine Market Size, by Region, 2017-2032 (USD Million)
TABLE 191. Africa Nanomaterial-Based Adjuvants Vaccine Market Size, by Vaccine Formulation, 2017-2032 (USD Million)
TABLE 192. Africa Nanomaterial-Based Adjuvants Vaccine Market Size, by mRNA, 2017-2032 (USD Million)
TABLE 193. Africa Nanomaterial-Based Adjuvants Vaccine Market Size, by Nanomaterial Type, 2017-2032 (USD Million)
TABLE 194. Africa Nanomaterial-Based Adjuvants Vaccine Market Size, by Inorganic Nanoparticles, 2017-2032 (USD Million)
TABLE 195. Africa Nanomaterial-Based Adjuvants Vaccine Market Size, by Lipid Nanoparticles, 2017-2032 (USD Million)
TABLE 196. Africa Nanomaterial-Based Adjuvants Vaccine Market Size, by Polymer Nanoparticles, 2017-2032 (USD Million)
TABLE 197. Africa Nanomaterial-Based Adjuvants Vaccine Market Size, by Virus-Like Particles, 2017-2032 (USD Million)
TABLE 198. Africa Nanomaterial-Based Adjuvants Vaccine Market Size, by Application, 2017-2032 (USD Million)
TABLE 199. Africa Nanomaterial-Based Adjuvants Vaccine Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 200. Africa Nanomaterial-Based Adjuvants Vaccine Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 201. Africa Nanomaterial-Based Adjuvants Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 202. Africa Nanomaterial-Based Adjuvants Vaccine Market Size, by Nasal, 2017-2032 (USD Million)
TABLE 203. Africa Nanomaterial-Based Adjuvants Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 204. Global Nanomaterial-Based Adjuvants Vaccine Market Size, by Group, 2017-2032 (USD Million)
TABLE 205. ASEAN Nanomaterial-Based Adjuvants Vaccine Market Size, by Group, 2017-2032 (USD Million)
TABLE 206. ASEAN Nanomaterial-Based Adjuvants Vaccine Market Size, by Vaccine Formulation, 2017-2032 (USD Million)
TABLE 207. ASEAN Nanomaterial-Based Adjuvants Vaccine Market Size, by mRNA, 2017-2032 (USD Million)
TABLE 208. ASEAN Nanomaterial-Based Adjuvants Vaccine Market Size, by Nanomaterial Type, 2017-2032 (USD Million)
TABLE 209. ASEAN Nanomaterial-Based Adjuvants Vaccine Market Size, by Inorganic Nanoparticles, 2017-2032 (USD Million)
TABLE 210. ASEAN Nanomaterial-Based Adjuvants Vaccine Market Size, by Lipid Nanoparticles, 2017-2032 (USD Million)
TABLE 211. ASEAN Nanomaterial-Based Adjuvants Vaccine Market Size, by Polymer Nanoparticles, 2017-2032 (USD Million)
TABLE 212. ASEAN Nanomaterial-Based Adjuvants Vaccine Market Size, by Virus-Like Particles, 2017-2032 (USD Million)
TABLE 213. ASEAN Nanomaterial-Based Adjuvants Vaccine Market Size, by Application, 2017-2032 (USD Million)
TABLE 214. ASEAN Nanomaterial-Based Adjuvants Vaccine Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 215. ASEAN Nanomaterial-Based Adjuvants Vaccine Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 216. ASEAN Nanomaterial-Based Adjuvants Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 217. ASEAN Nanomaterial-Based Adjuvants Vaccine Market Size, by Nasal, 2017-2032 (USD Million)
TABLE 218. ASEAN Nanomaterial-Based Adjuvants Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 219. GCC Nanomaterial-Based Adjuvants Vaccine Market Size, by Group, 2017-2032 (USD Million)
TABLE 220. GCC Nanomaterial-Based Adjuvants Vaccine Market Size, by Vaccine Formulation, 2017-2032 (USD Million)
TABLE 221. GCC Nanomaterial-Based Adjuvants Vaccine Market Size, by mRNA, 2017-2032 (USD Million)
TABLE 222. GCC Nanomaterial-Based Adjuvants Vaccine Market Size, by Nanomaterial Type, 2017-2032 (USD Million)
TABLE 223. GCC Nanomaterial-Based Adjuvants Vaccine Market Size, by Inorganic Nanoparticles, 2017-2032 (USD Million)
TABLE 224. GCC Nanomaterial-Based Adjuvants Vaccine Market Size, by Lipid Nanoparticles, 2017-2032 (USD Million)
TABLE 225. GCC Nanomaterial-Based Adjuvants Vaccine Market Size, by Polymer Nanoparticles, 2017-2032 (USD Million)
TABLE 226. GCC Nanomaterial-Based Adjuvants Vaccine Market Size, by Virus-Like Particles, 2017-2032 (USD Million)
TABLE 227. GCC Nanomaterial-Based Adjuvants Vaccine Market Size, by Application, 2017-2032 (USD Million)
TABLE 228. GCC Nanomaterial-Based Adjuvants Vaccine Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 229. GCC Nanomaterial-Based Adjuvants Vaccine Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 230. GCC Nanomaterial-Based Adjuvants Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 231. GCC Nanomaterial-Based Adjuvants Vaccine Market Size, by Nasal, 2017-2032 (USD Million)
TABLE 232. GCC Nanomaterial-Based Adjuvants Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 233. European Union Nanomaterial-Based Adjuvants Vaccine Market Size, by Group, 2017-2032 (USD Million)
TABLE 234. European Union Nanomaterial-Based Adjuvants Vaccine Market Size, by Vaccine Formulation, 2017-2032 (USD Million)
TABLE 235. European Union Nanomaterial-Based Adjuvants Vaccine Market Size, by mRNA, 2017-2032 (USD Million)
TABLE 236. European Union Nanomaterial-Based Adjuvants Vaccine Market Size, by Nanomaterial Type, 2017-2032 (USD Million)
TABLE 237. European Union Nanomaterial-Based Adjuvants Vaccine Market Size, by Inorganic Nanoparticles, 2017-2032 (USD Million)
TABLE 238. European Union Nanomaterial-Based Adjuvants Vaccine Market Size, by Lipid Nanoparticles, 2017-2032 (USD Million)
TABLE 239. European Union Nanomaterial-Based Adjuvants Vaccine Market Size, by Polymer Nanoparticles, 2017-2032 (USD Million)
TABLE 240. European Union Nanomaterial-Based Adjuvants Vaccine Market Size, by Virus-Like Particles, 2017-2032 (USD Million)
TABLE 241. European Union Nanomaterial-Based Adjuvants Vaccine Market Size, by Application, 2017-2032 (USD Million)
TABLE 242. European Union Nanomaterial-Based Adjuvants Vaccine Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 243. European Union Nanomaterial-Based Adjuvants Vaccine Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 244. European Union Nanomaterial-Based Adjuvants Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 245. European Union Nanomaterial-Based Adjuvants Vaccine Market Size, by Nasal, 2017-2032 (USD Million)
TABLE 246. European Union Nanomaterial-Based Adjuvants Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 247. BRICS Nanomaterial-Based Adjuvants Vaccine Market Size, by Group, 2017-2032 (USD Million)
TABLE 248. BRICS Nanomaterial-Based Adjuvants Vaccine Market Size, by Vaccine Formulation, 2017-2032 (USD Million)
TABLE 249. BRICS Nanomaterial-Based Adjuvants Vaccine Market Size, by mRNA, 2017-2032 (USD Million)
TABLE 250. BRICS Nanomaterial-Based Adjuvants Vaccine Market Size, by Nanomaterial Type, 2017-2032 (USD Million)
TABLE 251. BRICS Nanomaterial-Based Adjuvants Vaccine Market Size, by Inorganic Nanoparticles, 2017-2032 (USD Million)
TABLE 252. BRICS Nanomaterial-Based Adjuvants Vaccine Market Size, by Lipid Nanoparticles, 2017-2032 (USD Million)
TABLE 253. BRICS Nanomaterial-Based Adjuvants Vaccine Market Size, by Polymer Nanoparticles, 2017-2032 (USD Million)
TABLE 254. BRICS Nanomaterial-Based Adjuvants Vaccine Market Size, by Virus-Like Particles, 2017-2032 (USD Million)
TABLE 255. BRICS Nanomaterial-Based Adjuvants Vaccine Market Size, by Application, 2017-2032 (USD Million)
TABLE 256. BRICS Nanomaterial-Based Adjuvants Vaccine Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 257. BRICS Nanomaterial-Based Adjuvants Vaccine Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 258. BRICS Nanomaterial-Based Adjuvants Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 259. BRICS Nanomaterial-Based Adjuvants Vaccine Market Size, by Nasal, 2017-2032 (USD Million)
TABLE 260. BRICS Nanomaterial-Based Adjuvants Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 261. G7 Nanomaterial-Based Adjuvants Vaccine Market Size, by Group, 2017-2032 (USD Million)
TABLE 262. G7 Nanomaterial-Based Adjuvants Vaccine Market Size, by Vaccine Formulation, 2017-2032 (USD Million)
TABLE 263. G7 Nanomaterial-Based Adjuvants Vaccine Market Size, by mRNA, 2017-2032 (USD Million)
TABLE 264. G7 Nanomaterial-Based Adjuvants Vaccine Market Size, by Nanomaterial Type, 2017-2032 (USD Million)
TABLE 265. G7 Nanomaterial-Based Adjuvants Vaccine Market Size, by Inorganic Nanoparticles, 2017-2032 (USD Million)
TABLE 266. G7 Nanomaterial-Based Adjuvants Vaccine Market Size, by Lipid Nanoparticles, 2017-2032 (USD Million)
TABLE 267. G7 Nanomaterial-Based Adjuvants Vaccine Market Size, by Polymer Nanoparticles, 2017-2032 (USD Million)
TABLE 268. G7 Nanomaterial-Based Adjuvants Vaccine Market Size, by Virus-Like Particles, 2017-2032 (USD Million)
TABLE 269. G7 Nanomaterial-Based Adjuvants Vaccine Market Size, by Application, 2017-2032 (USD Million)
TABLE 270. G7 Nanomaterial-Based Adjuvants Vaccine Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 271. G7 Nanomaterial-Based Adjuvants Vaccine Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 272. G7 Nanomaterial-Based Adjuvants Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 273. G7 Nanomaterial-Based Adjuvants Vaccine Market Size, by Nasal, 2017-2032 (USD Million)
TABLE 274. G7 Nanomaterial-Based Adjuvants Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 275. NATO Nanomaterial-Based Adjuvants Vaccine Market Size, by Group, 2017-2032 (USD Million)
TABLE 276. NATO Nanomaterial-Based Adjuvants Vaccine Market Size, by Vaccine Formulation, 2017-2032 (USD Million)
TABLE 277. NATO Nanomaterial-Based Adjuvants Vaccine Market Size, by mRNA, 2017-2032 (USD Million)
TABLE 278. NATO Nanomaterial-Based Adjuvants Vaccine Market Size, by Nanomaterial Type, 2017-2032 (USD Million)
TABLE 279. NATO Nanomaterial-Based Adjuvants Vaccine Market Size, by Inorganic Nanoparticles, 2017-2032 (USD Million)
TABLE 280. NATO Nanomaterial-Based Adjuvants Vaccine Market Size, by Lipid Nanoparticles, 2017-2032 (USD Million)
TABLE 281. NATO Nanomaterial-Based Adjuvants Vaccine Market Size, by Polymer Nanoparticles, 2017-2032 (USD Million)
TABLE 282. NATO Nanomaterial-Based Adjuvants Vaccine Market Size, by Virus-Like Particles, 2017-2032 (USD Million)
TABLE 283. NATO Nanomaterial-Based Adjuvants Vaccine Market Size, by Application, 2017-2032 (USD Million)
TABLE 284. NATO Nanomaterial-Based Adjuvants Vaccine Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 285. NATO Nanomaterial-Based Adjuvants Vaccine Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 286. NATO Nanomaterial-Based Adjuvants Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 287. NATO Nanomaterial-Based Adjuvants Vaccine Market Size, by Nasal, 2017-2032 (USD Million)
TABLE 288. NATO Nanomaterial-Based Adjuvants Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 289. Global Nanomaterial-Based Adjuvants Vaccine Market Size, by Country, 2017-2032 (USD Million)
TABLE 290. United States Nanomaterial-Based Adjuvants Vaccine Market Size, 2017-2032 (USD Million)
TABLE 291. United States Nanomaterial-Based Adjuvants Vaccine Market Size, by Vaccine Formulation, 2017-2032 (USD Million)
TABLE 292. United States Nanomaterial-Based Adjuvants Vaccine Market Size, by mRNA, 2017-2032 (USD Million)
TABLE 293. United States Nanomaterial-Based Adjuvants Vaccine Market Size, by Nanomaterial Type, 2017-2032 (USD Million)
TABLE 294. United States Nanomaterial-Based Adjuvants Vaccine Market Size, by Inorganic Nanoparticles, 2017-2032 (USD Million)
TABLE 295. United States Nanomaterial-Based Adjuvants Vaccine Market Size, by Lipid Nanoparticles, 2017-2032 (USD Million)
TABLE 296. United States Nanomaterial-Based Adjuvants Vaccine Market Size, by Polymer Nanoparticles, 2017-2032 (USD Million)
TABLE 297. United States Nanomaterial-Based Adjuvants Vaccine Market Size, by Virus-Like Particles, 2017-2032 (USD Million)
TABLE 298. United States Nanomaterial-Based Adjuvants Vaccine Market Size, by Application, 2017-2032 (USD Million)
TABLE 299. United States Nanomaterial-Based Adjuvants Vaccine Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 300. United States Nanomaterial-Based Adjuvants Vaccine Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 301. United States Nanomaterial-Based Adjuvants Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 302. United States Nanomaterial-Based Adjuvants Vaccine Market Size, by Nasal, 2017-2032 (USD Million)
TABLE 303. United States Nanomaterial-Based Adjuvants Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 304. Canada Nanomaterial-Based Adjuvants Vaccine Market Size, 2017-2032 (USD Million)
TABLE 305. Canada Nanomaterial-Based Adjuvants Vaccine Market Size, by Vaccine Formulation, 2017-2032 (USD Million)
TABLE 306. Canada Nanomaterial-Based Adjuvants Vaccine Market Size, by mRNA, 2017-2032 (USD Million)
TABLE 307. Canada Nanomaterial-Based Adjuvants Vaccine Market Size, by Nanomaterial Type, 2017-2032 (USD Million)
TABLE 308. Canada Nanomaterial-Based Adjuvants Vaccine Market Size, by Inorganic Nanoparticles, 2017-2032 (USD Million)
TABLE 309. Canada Nanomaterial-Based Adjuvants Vaccine Market Size, by Lipid Nanoparticles, 2017-2032 (USD Million)
TABLE 310. Canada Nanomaterial-Based Adjuvants Vaccine Market Size, by Polymer Nanoparticles, 2017-2032 (USD Million)
TABLE 311. Canada Nanomaterial-Based Adjuvants Vaccine Market Size, by Virus-Like Particles, 2017-2032 (USD Million)
TABLE 312. Canada Nanomaterial-Based Adjuvants Vaccine Market Size, by Application, 2017-2032 (USD Million)
TABLE 313. Canada Nanomaterial-Based Adjuvants Vaccine Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 314. Canada Nanomaterial-Based Adjuvants Vaccine Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 315. Canada Nanomaterial-Based Adjuvants Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 316. Canada Nanomaterial-Based Adjuvants Vaccine Market Size, by Nasal, 2017-2032 (USD Million)
TABLE 317. Canada Nanomaterial-Based Adjuvants Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 318. Mexico Nanomaterial-Based Adjuvants Vaccine Market Size, 2017-2032 (USD Million)
TABLE 319. Mexico Nanomaterial-Based Adjuvants Vaccine Market Size, by Vaccine Formulation, 2017-2032 (USD Million)
TABLE 320. Mexico Nanomaterial-Based Adjuvants Vaccine Market Size, by mRNA, 2017-2032 (USD Million)
TABLE 321. Mexico Nanomaterial-Based Adjuvants Vaccine Market Size, by Nanomaterial Type, 2017-2032 (USD Million)
TABLE 322. Mexico Nanomaterial-Based Adjuvants Vaccine Market Size, by Inorganic Nanoparticles, 2017-2032 (USD Million)
TABLE 323. Mexico Nanomaterial-Based Adjuvants Vaccine Market Size, by Lipid Nanoparticles, 2017-2032 (USD Million)
TABLE 324. Mexico Nanomaterial-Based Adjuvants Vaccine Market Size, by Polymer Nan

Companies Mentioned

  • BioNTech SE
  • CSL Limited
  • Dynavax Technologies Corporation
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Vaxine Pty Ltd

Related Topics

Related Reports

Vaccine Adjuvants Market - Global Forecast 2026-2032 - Product Image

Vaccine Adjuvants Market - Global Forecast 2026-2032

  • Report
  • 196 Pages
  • Global
From
Oral Vaccine Adjuvants Market - Global Forecast 2026-2032 - Product Image

Oral Vaccine Adjuvants Market - Global Forecast 2026-2032

  • Report
  • 194 Pages
  • Global
From
Vaccine Adjuvants - Global Strategic Business Report - Product Image

Vaccine Adjuvants - Global Strategic Business Report

  • Report
  • 191 Pages
  • Global
From
Vaccine Adjuvants - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Vaccine Adjuvants - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 115 Pages
  • Global
From
Vaccine Adjuvants Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F - Product Image

Vaccine Adjuvants Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

  • Report
  • 180 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.